ABVC — ABVC Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- $15.41m
- $16.38m
- $0.51m
Annual cashflow statement for ABVC Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | C2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -10.6 | -12 | -16.3 | -8.28 | -5.26 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 6.3 | 5.22 | 7.39 | 3.18 | 3.66 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.086 | -1.61 | 0.636 | 0.422 | -0.41 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -4.56 | -7.6 | -7.4 | -4.19 | -1.81 |
| Capital Expenditures | — | -0.018 | -0.12 | -0.021 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.225 | -0.788 | -1.6 | -0.339 | 0 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.225 | -0.806 | -1.72 | -0.36 | 0 |
| Financing Cash Flow Items | — | -0.85 | 0 | -0.049 | 0.63 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 9.57 | 10 | 4.01 | 3.87 | 1.98 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 4.84 | 1.56 | -5.17 | -0.675 | 0.147 |